27 results on '"Loberiza, Fausto R."'
Search Results
2. Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Bhatt, Vijaya Raj, Balasetti, Vamshi, Jasem, Jagar A., Giri, Smith, Armitage, James O., Jr.Loberiza, Fausto R., Bociek, R. Gregory, Bierman, Philip J., Maness, Lori J., Vose, Julie M., Fayad, Pierre, Akhtari, Mojtaba, and Loberiza, Fausto R Jr
- Published
- 2015
- Full Text
- View/download PDF
3. Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence
- Author
-
Loberiza, Fausto R., Lee, Stephanie J., Klein, John P., Hassebroek, Anna, Dehn, Jason G., Frangoul, Haydar A., Hahn, Theresa, Hale, Gregory, Lazarus, Hillard M., LeMaistre, Charles F., Maziarz, Richard T., Rizzo, J. Douglas, and Majhail, Navneet S.
- Subjects
- *
STEM cell transplantation , *HEMATOPOIETIC stem cells , *LEUKEMIA , *MYELODYSPLASTIC syndromes , *SOCIAL status , *INCOME , *RURAL geography - Abstract
Studies suggest that patients who live in rural areas may have worse clinical outcomes compared with patients living in urban areas. We studied whether place of residence (rural versus urban) is associated with clinical outcomes of patients with leukemia or myelodysplastic syndrome (MDS) who received an unrelated donor hematopoietic cell transplantation (HCT). Patients'' residential ZIP code at the time of transplant was used to determine rural or urban designation based on the Rural Urban Commuting Codes. The study included 6140 patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 121 U.S. HCT centers: 1179 (19%) came from rural areas, whereas 4961 (81%) came from urban areas. Rural and urban patients were similar in patient-, disease-, and transplant-related characteristics aside from household income and distance traveled to the HCT center. After adjusting for income and other significant patient, disease, and transplant-related variables, the risk of overall mortality between patients residing in rural and urban areas were not statistically significant (relative risk 1.01, 95% confidence intervals 0.93-1.10, P = .74). Similar outcomes were noted for treatment-related mortality (TRM), disease-free survival (DFS), and relapse. Patient''s income, derived from the U.S. Census and based on their residential ZIP code, was independently associated with outcomes. In summary, our study showed no differences in the clinical outcomes of patients from rural or urban areas after unrelated donor HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
4. Methodological and Logistical Considerations to Study Design and Data Collection in Racial/Ethnic Minority Populations Evaluating Outcome Disparity in Hematopoietic Cell Transplantation
- Author
-
Loberiza, Fausto R., Lee, Stephanie J., Freytes, Cesar O., Giralt, Sergio A., Van Besien, Koen, Kurian, Seira, del Cerro, Paula, Toro, Juan J., Williams, Loretta A., Ketelsen, Seth W., Navarro, Willis H., and Douglas Rizzo, J.
- Subjects
- *
HEALTH & race , *HEALTH equity , *HEALTH outcome assessment , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *COHORT analysis , *SOCIODEMOGRAPHIC factors - Abstract
Abstract: Outcome disparity associated with race or ethnicity in the United States has been observed in hematopoietic cell transplantation (HCT). The underlying reasons for such disparity are not known. In the United States, an optimal study of health care disparity by race or ethnicity involves consideration of both biologic and psychosocial determinants, which requires an adequately powered, prospective cohort study design. To better characterize the nature and quantify the magnitude of the many impediments relevant to conducting a successful prospective study involving racial or ethnic minorities in HCT, we conducted a feasibility study to help guide planning of a larger scale outcome and disparity study in HCT. The primary questions to be addressed in the study were: (1) can we establish a racially or ethnically diverse patient sample that will respond to a survey focused on sociodemographic, economic, health insurance, cultural, spiritual, and religious well-being, and social support information? (2) What is the retention rate in the study over time? (3) What is the quality of the data collected from the patients over time? The challenges we faced in conducting this multicenter feasibility study are summarized in this report. Despite the difficulty in conducting disparity studies in racial and ethnic minorities, such studies are essential to ensure that people of all ethnic and racial backgrounds have the best chance possible of benefiting from HCT. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
5. Association of positive family history with survival of patients with lung cancer
- Author
-
Ganti, Apar Kishor, Loberiza, Fausto R., and Kessinger, Anne
- Subjects
- *
LUNG cancer patients , *GENEALOGY , *MEDICAL records , *SMOKING , *EPIDEMIOLOGY , *REGRESSION analysis - Abstract
Summary: Background: Risk factors for development of lung cancer include a family history of the disease. The effect of family history on lung cancer outcomes is unknown. A study was conducted to investigate this. Methods: The medical records of all patients with lung cancer seen in an academic medical oncology lung cancer clinic between 1999 and 2006 were reviewed for outcomes and family history of lung cancer. χ 2-test and Wilcoxon test were used for univariate comparisons, while Cox Proportional Hazards regression analysis was used to evaluate the adjusted risk of death. Univariate probability of survival was computed using Kaplan–Meier estimate and compared using the log-rank test. Results: Of the 560 patients evaluated, 289 (51%) were male and 519 (93%) had a smoking history. Of the 148 patients (26%) with a family history of lung cancer, 115 had an affected first-degree relative. No association between family history and histology or stage at diagnosis was detected. Median survival in patients with a family history of lung cancer was 53 months compared to 58 months in patients without such a history (p =0.06). Patients with a positive family history had an adjusted relative risk of death of 1.65 (95% CI: 1.07–2.56; p =0.02) compared to those without a family history. This risk was especially increased in those with an affected first-degree relative (RR: 1.72; 95% CI: 1.08–2.75, p =0.02). Conclusions: Lung cancer patients with a first-degree relative with lung cancer have a poorer outcome than those without such a history. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
6. A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model
- Author
-
Zhang, Xu, Loberiza, Fausto R., Klein, John P., and Zhang, Mei-Jie
- Subjects
- *
REGRESSION analysis , *MEDICAL research , *HEALTH outcome assessment , *SURVIVAL analysis (Biometry) , *EVALUATION of medical care , *COMPUTERS in medicine - Abstract
Abstract: Often in biomedical research the aim of a study is to compare the outcomes of several treatment arms while adjusting for multiple clinical prognostic factors. In this paper we focus on computation of the direct adjusted survival curves for different treatment groups based on an unstratified or a stratified Cox model. The estimators are constructed by taking the average of the individual predicted survival curves. The method of direct adjustment controls for possible confounders due to an imbalance of patient characteristics between treatment groups. This adjustment is especially useful for non-randomized studies. We have written a SAS macro to estimate and compare the direct adjusted survival curves. We illustrate the SAS macro through the examples analyzing stem cell transplant data and Ewing’s sarcoma data. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
7. Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
- Author
-
Navarro, Willis H., Loberiza, Fausto R., Bajorunaite, Ruta, van Besien, Koen, Vose, Julie M., Lazarus, Hillard M., and Rizzo, J. Douglas
- Subjects
- *
CELL transplantation , *CELLULAR therapy , *COHORT analysis - Abstract
Abstract: High-dose therapy with autologous hematopoietic cell transplantation (auto-HCT) is frequently used to improve outcomes in lymphoma. However, small studies suggest a survival disadvantage among obese patients. Using a retrospective cohort analysis, we studied the outcomes of 4681 patients undergoing auto-HCT for Hodgkin or non-Hodgkin lymphoma between 1990 and 2000 according to body mass index (BMI). Four groups categorized by BMI were compared by using Cox proportional hazards regression to adjust for other prognostic factors. A total of 1909 patients were categorized as normal weight (BMI 18-25 kg/m2), 121 as underweight (BMI <18 kg/m2), 1725 as overweight (BMI >25-30 kg/m2), and 926 as obese (BMI >30 kg/m2) at the time of HCT. Outcomes evaluated included overall survival, relapse, transplantation-related mortality (TRM), and lymphoma-free survival. TRM was similar among the normal, overweight, and obese groups; the underweight group had a higher risk of TRM (relative risk [RR], 2.46; 95% confidence interval [CI], 1.59-3.82; P < 0.0001) compared with the normal-BMI group. No differences in relapse were noted. Overall mortality was higher in the underweight group (RR, 1.48; 95% CI, 1.17-1.88; P = .001) and lower in the overweight (RR, 0.87; 95% CI, 0.79-0.96; P = .004) and obese (RR, 0.76; 95% CI, 0.67-0.86; P < .0001) groups compared with the normal-BMI group. In light of our inability to find differences in survival among overweight, obese, and normal-weight patients, obesity alone should not be viewed as a contraindication to proceeding with auto-HCT for lymphoma when it is otherwise indicated. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
8. What is quality in a transplant program?
- Author
-
LeMaistre, C. Fred and Loberiza, Fausto R.
- Subjects
- *
HEMATOPOIETIC stem cells , *BLOOD cells , *BONE marrow cells , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Abstract: Hematopoietic stem cell transplantation (HSCT) as a field of medicine has been subject to rapid development and evolution since its inception. Traditionally, HSCT has been used for therapy of a diverse group of malignancies, bone marrow failure states, and inherited disorders. The rapid evolution of transplantation technology coupled with the diverse outcomes associated with a heterogeneous group of patients has stymied the development of consensus over objective programmatic indicators of quality, especially as they pertain to outcomes. In some regard, the lack of consensus has caused transplant programs to respond to a more consumer-driven paradigm of evaluation. The community of providers of transplantation therapies has responded by establishing standards for accreditation of facilities and uniform presentation of programmatic data. Rapid acceptance of the need for meaningful quality programs to address all aspects of the transplant facility has moved HSCT to the forefront of implementing standards for medical practice. Because definition of optimal outcomes in HSCT is likely to remain elusive, it is imperative that providers involved with HSCT continue to take a leadership role in defining program quality through further research. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
9. Optimistic expectations and survival after hematopoietic stem cell transplantation
- Author
-
Lee, Stephanie J., Loberiza, Fausto R., Rizzo, J. Douglas, Soiffer, Robert J., Antin, Joseph H., and Weeks, Jane C.
- Subjects
- *
OPTIMISM , *MEDICAL consultants , *HEMATOPOIESIS - Abstract
An optimistic attitude is hypothesized to be beneficial when facing a life-threatening medical condition. However, the actual relationship of high expectations for treatment success and medical outcome is controversial. Using a prospective cohort of 313 autologous and allogeneic hematopoietic stem cell transplant patients enrolled July 1996 through November 1999, we tested whether patient-reported expectations before transplantation were associated with survival and quality of life following the procedure. Before transplantation, patients with higher expectations that the transplant procedure would go well had better mental and emotional functioning, but similar physical status and medical condition to patients with less optimistic expectations. In the first 2 months after transplantation, optimistic expectations were associated with better survival (92% v 84%; relative risk for mortality 0.45, 95% confidence interval 0.22–0.92; P=.03) controlling for other physical and mental characteristics. However, by 6 months posttransplantation, survival and quality of life were indistinguishable between patients with initially higher and lower expectations. Our data suggest an association between more optimistic expectations and early survival following hematopoietic stem cell transplantation, but this association is not present by 6 months posttransplantation. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
10. Practice Mapping in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL): The Use of Measurable Residual Disease (MRD) Assessment in Real-World U.S. Community Oncology Practice.
- Author
-
Welch, Verna L., Klink, Andrew J., Loberiza, Fausto R., Neuhof, Alexander, Lord, Kevin, and Feinberg, Bruce
- Published
- 2019
- Full Text
- View/download PDF
11. Erratum to “A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model” [Comput. Meth. Prog. Biomed. 88 (2007) 95–101]
- Author
-
Zhang, Xu, Loberiza, Fausto R., Klein, John P., and Zhang, Mei-Jie
- Published
- 2008
- Full Text
- View/download PDF
12. Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma.
- Author
-
William, Basem M., Allen, Mary S., Loberiza, Fausto R., Bociek, Robert Gregory, Bierman, Philip J., Armitage, James O., and Vose, Julie M.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *BORTEZOMIB , *LYMPHOMAS , *DRUG efficacy , *MEDICATION safety , *CANCER relapse , *AUTOTRANSPLANTATION , *CLINICAL trials - Abstract
Abstract: A phase I/II trial was designed to evaluate the safety and efficacy of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (ASCT). Eligible patients had relapsed/refractory indolent or transformed non-Hodgkin lymphoma or mantle cell lymphoma (MCL) that was relapsed/refractory or in first partial (PR) or complete remission (CR). Patients received bortezomib on days −11, −8, −5, and −2 before ASCT. Phase I had 4 dose cohorts (.8, 1, 1.3, and 1.5 mg/m2) and 3 patients were accrued to each. Any nonhematological ASCT-related toxicity >2 on the Bearman scale occurring between day −11 and engraftment defined the maximum tolerated dose (MTD). After the MTD has been reached, another 20 patients were enrolled at this dose to determine a preliminary overall response rate (ORR). Patients who were in CR or PR at day +100 were considered responders. The study enrolled 42 patients through August 14, 2009. The median age was 58 (range, 34 to 73) years, with 33 males and 9 females. The most common diagnoses were MCL (23 patients) and follicular lymphoma (7 patients). The median number of prior therapies was 1 (range, 0 to 6). The median follow-up was 4.88 (range, 1.07 to 6.98) years. Thirteen patients were treated in phase I and 29 patients were treated in phase II. The MTD was initially determined to be 1.5 mg/m2 but it was later decreased to 1 mg/m2 because of excessive gastrointestinal toxicity and peripheral neuropathy. The ORR was 95% at 100 days and 87% at 1 year. For all 38 evaluable patients at 1 year, responses were CR 84%, PR 1%, and progressive disease 13%. Progression-free survival (PFS) was 83% (95% CI, 68% to 92%) at 1 year, and 32% (15% to 51%) at 5 years. Overall survival (OS) was 91% (95% CI, 79% to 96%) at 1 year and 67% (50% to 79%) at 5 years. The most common National Cancer Institute grade 3 toxicities were neutropenic fever (59%), anorexia (21%), peripheral neuropathy (19%), orthostatic hypotension/vasovagal syncope (16%), and 1 patient failed to engraft. Compared with 26 MCL in CR1 historic controls treated with BEAM and ASCT, PFS was 85% and 43% for the BEAM group versus 87% and 57% for those who received bortezomib in addition to standard BEAM (V-BEAM) at 1 and 5 years, respectively (log-rank P = .37). OS was 88% and 50% for the BEAM group versus 96% and 72% for V-BEAM at 1 and 5 years, respectively (log-rank P = .78). In conclusion, V-BEAM and ASCT is feasible. The toxicities were manageable and we did not observe any treatment-related mortalities; however, we did observe an excess of autonomic dysfunction and ileus, which is concerning for overlapping toxicity with BEAM conditioning. Determining relative efficacy of V-BEAM compared to BEAM would require a randomized trial. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
13. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
- Author
-
Vose, Julie M., Bierman, Philip J., Loberiza, Fausto R., Enke, Charles, Hankins, Jordan, Bociek, Robert G., Chan, Wing C., Weisenburger, Dennis D., and Armitage, James O.
- Subjects
- *
STEM cell transplantation , *IODINE isotopes , *LYMPHOMA treatment , *DRUG therapy , *HODGKIN'S disease , *CARMUSTINE , *ETOPOSIDE - Abstract
Abstract: The purpose of this study was to evaluate the standard outpatient dose of 131-Iodine tositumomab (75 cGy) combined with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) followed by autologous stem cell rescue for the treatment of chemotherapy-sensitive relapsed or refractory, or high-risk first complete remission (CR) patients with diffuse large B cell non-Hodgkin''s lymphoma (DLBCL). Forty patients with chemotherapy-sensitive persistent or relapsed or high/intermediate or high international prognostic index DLCBL were treated in a phase II trial combining 75 cGy 131-Iodine tositumomab with high-dose BEAM followed by autologous stem cell transplantation. The CR rate after transplantation was 78%, and the overall response rate was 80%. Short-term and long-term toxicities were similar to historical control patients treated with BEAM alone. With a median follow-up of 6 years (range, 3-10 years), the 5-year overall survival (OS) was 72% (95% confidence interval [CI], 55%-83%), and the 5-year progression-free survival (PFS) rate was 70% (95% CI, 53%-82%). The PFS and OS were encouraging in this group of chemotherapy-sensitive persistent, relapsed, or high-risk patients with DLBCL. A follow-up phase III trial with 131-Iodine tositumomab/BEAM vs rituximab/BEAM was planned based on this information. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
14. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview
- Author
-
Azim, Hatem A., Elattar, Inas, Loberiza, Fausto R., Azim, Hamdy, Mok, Tony, and Ganti, Apar Kishor
- Subjects
- *
LUNG cancer treatment , *CANCER chemotherapy , *HEALTH outcome assessment , *META-analysis , *COMBINATION drug therapy , *ANTINEOPLASTIC agents , *CLINICAL trials - Abstract
Abstract: Background: Previous meta-analysis on three drugs combination for treatment of advanced non-small cell lung cancer (NSCLC) did not demonstrate an improvement in survival, however many of the trials included in this meta-analysis used older and less effective cytotoxic drugs. We conducted this analysis to compare the relative efficacy of third generation triplet therapy with that of standard double therapy in the treatment of advanced NSCLC. Methods: A MEDLINE search was performed using the search terms “lung cancer” and “randomized trials”. Trials not utilizing a third generation cytotoxic chemotherapeutic agent (paclitaxel, docetaxel, vinorelbine, gemcitabine) were excluded. Pooled odds ratios (OR) for the objective response and toxicity rates were calculated using the Mantel-Haenszel estimate. Pooled median ratios for median survival were calculated using the weighted sum of the log-ratio of median ratios of individual study. Results: We analyzed six randomized comparative trials involving 1932 patients. Patients receiving triplet therapy had a significantly higher response rate (OR: 1.33; 95% CI, 1.50–2.23; P <0.001). Incidence of grade III/IV hematological toxicity was higher with triplet therapy. Non-hematological toxicities, with the exception of neuropathy, were similar. Median survival of triplet therapy was not significantly different from doublet (MR: 1.10; 95% CI: 0.91–1.35; P =0.059). Conclusions: Triplet therapy with third generation cytotoxic drugs is associated with higher tumor response rate at the expense of increased toxicity. Although triplet therapy had a better overall survival compared to doublet therapy, this did not reach statistical significance. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
15. Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index
- Author
-
Vose, Julie M., Bierman, Philip J., Loberiza, Fausto R., Lynch, James C., Bociek, Gregory R., Weisenburger, Dennis D., and Armitage, James O.
- Subjects
- *
STEM cells , *TRANSPLANTATION of organs, tissues, etc. , *CELL transplantation , *CELLULAR therapy - Abstract
Abstract: Although results of autologous stem cell transplantation (SCT) for recurrent follicular non-Hodgkin lymphoma (NHL) have been previously reported, the long-term results and evaluation of prognostic factors in a large patient population receiving this therapy are difficult to find in the literature. To address these issues, we evaluated 248 patients with recurrent follicular NHL treated with high-dose chemotherapy and autologous SCT between 7/87 and 6/03. According to the World Health Organization (WHO) classification system, 64 patients (26%) had follicular NHL grade 1 (FL 1), 98 (40%) had FL 2, and 86 (35%) had FL 3. At the time of transplantation, 88 of the patients (35%) had a Follicular Lymphoma International Prognostic Index (FLIPI) score of low risk, 87 (35%) had an intermediate-risk FLIPI score, 37 (15%) had a high-risk FLIPI score, and 36 (15%) had at least 1 missing value, preventing calculation of the FLIPI score. The 5-year overall survival (OS) for all patients was 63%, and the 5-year progression-free survival (PFS) was 44%. In a multivariate analysis, a histological grade of FL 3, a high-risk FLIPI score at the time of transplantation, and having received 3 or more previous chemotherapy regimens were significant factors for predicting a worse OS. In addition, the use of a transplantation regimen including a monoclonal antibody decreased the relative risk of progressive lymphoma. These data suggest that transplantation earlier in the course of the disease for patients with follicular lymphoma with use of a monoclonal antibody–based regimen may lead to improved outcomes. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
16. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
- Author
-
Ho, Vincent T., Martin, Andrew St., Pérez, Waleska S., Steinert, Patricia, Zhang, Mei-Jie, Chirnomas, Deborah, Hoang, Caroline J., Loberiza, Fausto R., and Saber, Wael
- Subjects
- *
HEPATIC veno-occlusive disease , *ACUTE myeloid leukemia , *CELL transplantation , *BONE marrow , *TRANSPLANTATION of organs, tissues, etc. - Abstract
• VOD/SOS incidence at 100 days post-HCT was 4% versus 3% in GO-exposed adults versus control subjects. • Five-year overall survival probability was 38% in both groups. • GO exposure before HCT was not associated with an increased risk of VOD/SOS or death. Gemtuzumab ozogamicin (GO) therapy before allogeneic hematopoietic cell transplantation (alloHCT) has been historically associated with an increased risk of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients with acute myeloid leukemia (AML). The current analysis examined VOD/SOS risk and outcomes in a cohort of patients who in recent years were reported to the Center for International Blood and Marrow Transplant Research. Adults with AML who had GO exposure before myeloablative alloHCT were matched 1:4 by age and disease status at transplant to recipients without GO exposure (control subjects). One hundred thirty-seven patients with GO exposure and 548 matched control subjects who underwent alloHCT between 2008 and 2011 were included in this analysis. With a median ∼8-year follow-up of survivors, the 5-year overall survival probability was similar in the 2 cohorts: 38% and 38% in the GO-exposed versus control groups (P =.97). Incidence of VOD/SOS and severe VOD/SOS, respectively, at 100 days was 4% (95% confidence interval [CI], 1% to 7%) and 3% (95% CI, 1% to 6%) in GO-exposed patients and 3% (95% CI, 2% to 5%) and 1% (95% CI, 0% to 2%) in control subjects. Correspondingly, among patients who developed VOD/SOS, 1-year survival probability after VOD/SOS diagnosis was 33% (95% CI, 5% to 72%) and 27% (95% CI, 11% to 47%; P =.78). In multivariate analyses, GO exposure before alloHCT was not associated with an increased risk of VOD/SOS (odds ratio, 1.10; P =.85) or death (hazard ratio, 1.08; P =.57). Three deaths (3%) in the GO group and 3 deaths (<1%) in the control group were attributed to VOD/SOS. Our results suggest that GO treatment before myeloablative alloHCT in the recent era is not associated with an increased risk of post-transplant VOD/SOS or death. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
- Author
-
Lazarus, Hillard M., Carreras, Jeanette, Boudreau, Christian, Loberiza, Fausto R., Armitage, James O., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Gibson, John, Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Miller, Alan M., Pavlovsky, Santiago, Schouten, Harry C., van Besien, Koen, Vose, Julie M., and Bitran, Jacob D.
- Subjects
- *
HODGKIN'S disease , *CELL transplantation , *HEMATOPOIETIC stem cells , *BONE marrow transplantation , *HEALTH outcome assessment , *MULTIVARIATE analysis , *MEDICAL care research , *PATIENTS - Abstract
Abstract: To compare the clinical outcomes of older (age ≥55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged ≥55 years to 1949 NHL patients <55 years during the years 1990–2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). In multivariate analysis, older patients with aggressive histologies were 1.86 times (95% confidence interval [CI] 1.43-2.43, P < .001) more likely than younger patients to experience treatment-related mortality (TRM). Relative death risks were 1.33 times (CI 1.04-1.71, P = .024) and 1.50 times (CI 1.33-16.9, P < .001) higher in older compared to younger patients with follicular grade I/II and aggressive histologies, respectively. Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients. Studies addressing supportive care particular to older patients, who are most likely to benefit from this approach, are recommended. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
18. Variation in Supportive Care Practices in Hematopoietic Cell Transplantation
- Author
-
Lee, Stephanie J., Astigarraga, Claudia C., Eapen, Mary, Artz, Andrew S., Davies, Stella M., Champlin, Richard, Jagasia, Madan, Kernan, Nancy A., Loberiza, Fausto R., Bevans, Margaret, Soiffer, Robert J., and Joffe, Steven
- Subjects
- *
CELLULAR therapy , *CELL transplantation , *CELLS , *STEM cells - Abstract
Hematopoietic cell transplantation is an elective procedure that results in prolonged immune suppression and high treatment-related morbidity and mortality. Transplant centers and physicians use a variety of prophylaxis and monitoring strategies to prevent or minimize complications. Little is known about the variability in these practices. We conducted an international Internet-based survey of 526 physicians to describe the spectrum of supportive care practices employed. Consistency in pretransplant cardiac (96%) and pulmonary (95%) screening, informed consent documentation (93%), and use of antifungal prophylaxis (92%) was observed. Greater heterogeneity was seen in use of myelogenous growth factors, empiric antibiotic therapy, protective isolation procedures, posttransplant monitoring, and environmental and social restrictions. Although some practice differences were associated with physician characteristics and transplant type, most practice variation remained unexplained. These results suggest a need for well-designed observational and interventional studies to provide data about which supportive care practices improve outcomes. For practices proved to be beneficial, publication of guidelines and incorporation of monitoring into quality improvement initiatives may help standardize practices. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
19. Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence
- Author
-
Rao, Keshav, Darrington, Deborah L., Schumacher, Joseph J., Devetten, Marcel, Vose, Julie M., and Loberiza, Fausto R.
- Subjects
- *
STEM cells , *HEMATOPOIETIC stem cells , *CELL transplantation , *CELLULAR therapy - Abstract
We evaluated whether or not a patient''s area of primary residence is an independent risk factor for overall survival (OS) after HLA-identical sibling or autologous hematopoietic stem cell transplantation (HSCT). This retrospective cohort study included patients who underwent autologous (n = 1739) or HLA-identical sibling (n = 267) HSCT to treat a hematologic malignancy between 1983 and 2004 at the University of Nebraska Medical Center. Primary area of residence, using the patient''s zip code, was categorized as either urban or rural (including isolated, small rural, or large rural) according to the Rural Urban Commuting Area Codes (RUCA) classification system. An association between area of primary residence and survival was examined using Cox proportional hazards regression analysis while adjusting for patient-, disease-, and treatment-related variables. Patients from rural areas who received autologous HSCT had a higher relative risk of death (relative risk = 1.18; P = .016) than urban patients who underwent the same procedure. Survival rates in patients from rural and urban locations are as follows: 1 year, 73% vs 78% (P = .04); 5 year, 48% vs 54% (P = .012). We failed to detect a significant difference in the risk of death according to primary area of residence in the HLA-identical sibling HSCT cohort, although this may be from lack of statistical power. Our findings suggest that the primary location of a patient''s residence may be an independent risk factor for survival after HSCT. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
20. Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation
- Author
-
Loren, Alison W., Bunin, Greta R., Boudreau, Christian, Champlin, Richard E., Cnaan, Avital, Horowitz, Mary M., Loberiza, Fausto R., and Porter, David L.
- Subjects
- *
STEM cells , *TRANSPLANTATION of organs, tissues, etc. , *CELL transplantation , *GRAFT versus host disease - Abstract
Abstract: Allogeneic hematopoietic stem cell transplantation (SCT) may cure patients with hematologic malignancies, but it carries significant risks. Careful donor selection is an important component of the clinical transplantation decision-making process and includes evaluation of HLA typing and other criteria, the most controversial of which is parity. We examined the effect of donor sex and parity on outcomes of HLA-identical sibling SCT. Because the effect of recipient sex/parity has never been explicitly evaluated, we also analyzed the effect of recipient sex/parity on outcomes of transplantation. We found that (1) parous female donors result in an increased risk of chronic graft-versus-host disease (GVHD) in all recipients, (2) the magnitude of this increased risk is similar in male and female recipients, and (3) nulliparous female donors increase the risk of chronic GVHD in male recipients to a degree comparable to that from parous donors. A decrease in the risk of relapse was not observed, and there was no effect on overall survival, acute GVHD, or transplant-related mortality. Recipient parity had no independent effect on any endpoint. Until the effects of pregnancy on the maternal immune system are better understood, it is appropriate whenever possible to avoid parous female donors and to choose male donors for male recipients in HLA-identical related donor SCT. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
21. Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities
- Author
-
Schwake, Christopher J., Eapen, Mary, Lee, Stephanie J., Freytes, César O., Giralt, Sergio A., Navarro, Willis H., Rizzo, J. Douglas, van Besien, Koen, and Loberiza, Fausto R.
- Subjects
- *
STEM cells , *HEMATOPOIETIC stem cells , *PHYSICIANS , *PHYSICIAN-patient relations - Abstract
Abstract: Racial or ethnic minorities with leukemia who receive HLA-identical sibling hematopoietic stem cell transplants (HSCTs) are reported to have worse survival when compared with whites. Characteristics of US HSCT centers according to the proportion of ethnic minorities who undergo transplantation were compared to explore systematic differences among centers; the association with 100-day mortality was evaluated to determine whether center factors may explain the observed discrepant survival among ethnic minorities. One hundred sixteen US transplantation centers that performed HLA-identical sibling transplantations for leukemia were analyzed. We compared physician and health care provider staffing, transplantation unit procedure and resources, and medical center organization according to the volume procedure ratio of ethnic minorities who underwent transplantation and also according to the ratio of Hispanics who underwent transplantation. Centers that performed transplantation in a higher proportion of ethnic minorities were more likely to perform fewer transplantations per year, to have fewer devoted transplant beds, to be in an urban setting, to have a lower physician to patient volume ratio, and to follow up survivors 1 year after transplantation. Centers that performed transplantation in a higher proportion of Hispanics were more likely to perform fewer transplantations per year and to have fewer devoted transplantation beds, were less likely to perform outpatient transplantations, were more likely to be in an urban setting, and were less likely to have posttransplantation immunization protocols. Observed differences in center factors were not associated with 100-day mortality after adjustment for disease severity. Our results suggest that the inferior survival reported in ethnic minorities after HSCT may not be readily explained by center effects. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
22. ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited
- Author
-
Seebach, Jörg D., Stussi, Georg, Passweg, Jakob R., Loberiza, Fausto R., Gajewski, James L., Keating, Armand, Goerner, Martin, Rowlings, Philip A., Tiberghien, Pierre, Elfenbein, Gerald J., Gale, Robert Peter, van Rood, Jon J., Reddy, Vijay, Gluckman, Eliane, Bolwell, Brian J., Klumpp, Thomas R., Horowitz, Mary M., Ringdén, Olle, and Barrett, A. John
- Subjects
- *
BONE marrow transplantation , *IMMUNE system , *LEUKEMIA , *GRAFT versus host disease - Abstract
Abstract: Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P < .001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
23. Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients
- Author
-
Lazarus, Hillard M., Koc, Omer N., Devine, Steven M., Curtin, Peter, Maziarz, Richard T., Holland, H. Kent, Shpall, Elizabeth J., McCarthy, Philip, Atkinson, Kerry, Cooper, Brenda W., Gerson, Stanton L., Laughlin, Mary J., Loberiza, Fausto R., Moseley, Annemarie B., and Bacigalupo, Andrea
- Subjects
- *
PLANT diseases , *GRAFT versus host disease , *IMMUNE system , *PRESERVATION of organs, tissues, etc. - Abstract
Abstract: Mesenchymal stem cells (MSCs) are found in a variety of tissues, including human bone marrow; secrete hematopoietic cytokines; support hematopoietic progenitors in vitro; and possess potent immunosuppressive properties. We hypothesized that cotransplantation of culture-expanded MSCs and hematopoietic stem cells (HSCs) from HLA-identical sibling donors after myeloablative therapy could facilitate engraftment and lessen graft-versus-host disease (GVHD); however, the safety and feasibility of this approach needed to be established. In an open-label, multicenter trial, we coadministered culture-expanded MSCs with HLA-identical sibling-matched HSCs in hematologic malignancy patients. Patients received either bone marrow or peripheral blood stem cells as the HSC source. Patients received 1 of 4 study-specified transplant conditioning regimens and methotrexate (days 1, 3, and 6) and cyclosporine as GVHD prophylaxis. On day 0, patients were given culture-expanded MSCs intravenously (1.0¿5.0 × 106/kg) 4 hours before infusion of either bone marrow or peripheral blood stem cells. Forty-six patients (median age, 44.5 years; range, 19¿61 years) received MSCs and HLA-matched sibling allografts. MSC infusions were well tolerated, without any infusion-related adverse events. The median times to neutrophil (absolute neutrophil count ¿0.500 × 109/L) and platelet (platelet count ¿20 × 109/L) engraftment were 14.0 days (range, 11.0¿26.0 days) and 20 days (range, 15.0¿36.0 days), respectively. Grade II to IV acute GVHD was observed in 13 (28%) of 46 patients. Chronic GVHD was observed in 22 (61%) of 36 patients who survived at least 90 days; it was extensive in 8 patients. Eleven patients (24%) experienced relapse at a median time to progression of 213.5 days (range, 14¿688 days). The probability of patients attaining disease- or progression-free survival at 2 years after MSC infusion was 53%. Cotransplantation of HLA-identical sibling culture-expanded MSCs with an HLA-identical sibling HSC transplant is feasible and seems to be safe, without immediate infusional or late MSC-associated toxicities. The optimal MSC dose and frequency of administration to prevent or treat GVHD during allogeneic HSC transplantation should be evaluated further in phase II clinical trials. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
24. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
- Author
-
Vose, Julie M., Rizzo, Douglas J., Tao-Wu, Jing, Armitage, James O., Bashey, Asad, Burns, Linda J., Christiansen, Neal Paul, Freytes, Cesar O., Gale, Robert Peter, Gibson, John, Giralt, Sergio A., Herzig, Roger H., Lemaistre, Charles F., McCarthy Jr, Philip L., Nimer, Stephen D., Petersen, Finn B., Schenkein, David P., Wiernik, Peter H., Wiley, Joseph M., and Loberiza, Fausto R.
- Subjects
- *
DRUG therapy , *STEM cell transplantation , *LYMPHOMAS - Abstract
We evaluated the results of high-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with diffuse aggressive non-Hodgkin lymphoma (NHL) in first relapse (Rel 1) or second complete remission (CR 2). Data were evaluated from the Autologous Blood and Marrow Transplant Registry on 429 patients with diffuse aggressive NHL who underwent transplantation in Rel 1 or CR 2. Transplantations were performed between 1989 and 1996 and were reported to the Autologous Blood and Marrow Transplant Registry by 93 centers in North and South America. The probability of 3-year survival was 44% (95% confidence interval [CI], 33%–55%). The probability at 3 years of progression-free survival was 31% (95% CI, 27%–36%). Patients who underwent transplantation in CR 2 had a 3-year probability of progression-free survival of 38% (95% CI, 30%–46%) compared with 28% (95% CI, 22%–33%) for those who were not in remission at the time of transplantation (P < .001). In multivariate analysis, chemotherapy resistance, increased lactic dehydrogenase at diagnosis, an interval of <12 months from diagnosis to relapse, age ≥40 years, and use of myeloid growth factors to accelerate posttransplantation bone marrow recovery were adverse predictors of survival. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with diffuse aggressive NHL in CR 2 or Rel 1 resulted in better outcome for patients with chemotherapy-sensitive disease, longer relapse-free intervals, and age <40 years. Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
25. 434 - Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT).
- Author
-
Ho, Vincent T., Martin, Andrew St, Perez, Waleska, Steinert, Patricia, Zhang, Mei-Jie, Chirnomas, Deborah, Hoang, Caroline J., Loberiza, Fausto R., and Saber, Wael
- Published
- 2018
- Full Text
- View/download PDF
26. 435 - Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant.
- Author
-
Duncan, Christine, St Martin, Andrew, Perez, Waleska, Steinert, Patricia, Zhang, Mei-Jie, Chirnomas, Deborah, Hoang, Caroline J., Loberiza, Fausto R., and Saber, Wael
- Published
- 2018
- Full Text
- View/download PDF
27. 44 - Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
- Author
-
Kebriaei, Partow, Stelljes, Matthias, DeAngelo, Daniel J., Gökbuget, Nicola, Kantarjian, Hagop, Advani, Anjali S., Merchant, Akil, Stock, Wendy, Wang, Tao, Zhang, Hui, Loberiza, Fausto R., Vandendries, Erik, and Marks, David I.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.